Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Pfizer gets global rights to Scil's rhCD-RAP; rights returned

Executive Summary

Pfizer licensed exclusive worldwide rights to develop and commercialize Scil Technology GMBH's cartilage growth factor called recombinant human cartilage-derived retinoic acid-sensitive protein, or rhCD-RAP. Scil is a division of BioNet Holding that concentrates on biomaterials for bone and cartilage repair.
Deal Industry
  • Pharmaceuticals
  • Medical Devices
    • Biomaterials
  • Biotechnology
    • Large Molecule
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies